Explore ›
Finding
Finding
decline
Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), representing a prescribing disparity in guideline-based cardiovascular pharmacotherapy.
| Effect size | adjusted OR 0.73 |
| CI | 95% CI = 0.67-0.8 |
| Comparator | Non-IDD patients with ASCVD in the same commercially insured database (n=790,343) |
| Effect summary | decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8 |
| Effect modifiers | [{"modifier": "IDD subtype (Down syndrome)", "interaction_p": "", "direction": "amplifies", "stratum_details": "Down syndrome vs autism spectrum disorder: adjusted OR 0.51, 95% CI 0.32-0.80 for statin use", "plain_language": "Patients with Down syndrome had even lower statin prescribing rates compared to other IDD subtypes", "annotation_notes": "Subgroup analysis within IDD patients, with autism spectrum disorder as reference group"}] |
Connected entities
Interventions
Outcomes
Source
PMC8009695
Disparities in the Use of Guideline-Based Pharmacotherapy Exist for Atherosclerotic Cardiovascular Disease and Heart Failure Patients Who Have Intellectual/Developmental Disabilities in a Commercially Insured Database